EUVIMEDOpdag EUVIMED
Crossref

Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer

Cyrille K Cornelio iD, Kevin Cowart iD, Janelle Perkins iD, Mohammed E Alomar, Ricardo Pineda Gayoso, Aimon C Miranda iD, Anh T Phan, Raechel T White iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026

DOI: 10.1002/phar.70130 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Written by Cyrille K Cornelio and 7 co-authors. Institution: Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Breast Neoplasms, Cardiovascular Diseases. Cited 3 times so far (Crossref); 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The cardiovascular (CV) benefits of glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) therapies are not well‐established in women with breast cancer and type 2 diabetes (T2D).

Objectives

The primary objective of this study was to compare the incidence of major adverse cardiovascular events (MACE) in women with T2D and breast cancer receiving GLP‐1 RA therapy versus non‐GLP‐1 RA diabetes medications.

Methods

This retrospective study included women with T2D, diagnosed with breast cancer at ≥ 40 years old from December 16, 2014 to December 16, 2024 and having exposure to diabetes medications of interest (either GLP‐1 RA or non‐GLP‐1 RA) within 5 years of these diagnoses. The primary end point, MACE, was a composite of myocardial infarction, ischemic stroke, coronary revascularization, cardiac arrest, or heart failure, within 5 years of the index date. Propensity score matching was performed. Participants were excluded from each individual outcome analysis if they had the outcome prior to the index date. Incidence rates, risk ratio (RR), 95% confidence interval (CI), and p ‐value were reported for each outcome.

Results

After matching, 19,608 patients were included in each cohort (mean age 64 years). Obesity and alkylating agents were more commonly reported in the GLP‐1 RA cohort. Semaglutide was the most prescribed GLP‐1 RA at index (45.1%). MACE occurred in 10.6% of the GLP‐1 RA cohort and 13.4% of the non‐GLP‐1 cohort (RR 0.80, 95% CI 0.75–0.85, p < 0.001). Individual MACE end points, ischemic heart disease, and end‐stage renal disease were significantly lower in the GLP‐1 RA‐treated cohort. GLP‐1 RA use was also associated with a 61.6% relative risk reduction in all‐cause mortality (RR 0.38, 95% CI 0.36–0.41, p < 0.001). Pancreatitis incidence was similar between groups ( p = 0.057), whereas cholelithiasis was significantly lower with GLP‐1 RA therapy ( p < 0.001).

Conclusions

This study demonstrated the potential CV benefit of GLP‐1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsBreast NeoplasmsCardiovascular DiseasesHypoglycemic AgentsHumansFemaleMiddle AgedRetrospective StudiesAgedIncidenceSemaglutideAdult

Author keywords

breast cancercancer survivorshipcardiovascular risk reductionglucagon‐like‐peptide‐1 receptor agonists

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutide

Authors and institutions

  • Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Department of Pharmacy, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.

ORCID profiles: Cyrille K Cornelio, Kevin Cowart, Janelle Perkins, Aimon C Miranda, Raechel T White

Cite

APA

Cornelio, C. K., Cowart, K., Perkins, J., Alomar, M. E., Gayoso, R. P., Miranda, A. C., Phan, A. T., & White, R. T. (2026). Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70130

Vancouver

Cornelio CK, Cowart K, Perkins J, Alomar ME, Gayoso RP, Miranda AC, et al. Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70130

BibTeX
@article{Cornelio2026,
  author = {Cornelio, Cyrille K and Cowart, Kevin and Perkins, Janelle and Alomar, Mohammed E and Gayoso, Ricardo Pineda and Miranda, Aimon C and Phan, Anh T and White, Raechel T},
  title = {Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  doi = {10.1002/phar.70130}
}
Start for free →